Wegovy, 1.7 Mg, Pre-Filled Pen - 1 Pen

Novo Nordisk

Weight Loss Medications / Anti-Obesity Drugs

Wegovy contains semaglutide, a synthetic analog of the human GLP-1 hormone.
Produced using recombinant DNA technology in yeast cells.
Targets brain areas responsible for appetite regulation, reducing calorie intake.
Available as a weekly subcutaneous injection using prefilled pens.

Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adults with:
- An initial Body Mass Index (BMI) of ≥30 kg/m² (obesity)
- A BMI of ≥27 kg/m² to <30 kg/m² (overweight) in the presence of at least one weight-related comorbidity (such as prediabetes, type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease).

Helps with significant weight loss when combined with a low-calorie diet and increased physical activity.
Reduces appetite and slows stomach emptying, promoting satiety.
Effective for patients with weight-related health conditions like diabetes and cardiovascular disease.

Not recommended for patients with severe renal impairment (eGFR <30 mL/min/1.73m²) or end-stage renal disease.
Not recommended for patients with severe hepatic impairment; use cautiously in patients with mild to moderate hepatic impairment.
May cause gastrointestinal adverse reactions that can lead to dehydration. Patients should take precautions to avoid fluid depletion.
Acute pancreatitis has been observed with GLP-1 receptor agonists. Discontinue if pancreatitis is suspected.
Should not be used as a substitute for insulin in patients with type 2 diabetes.
Not to be used in combination with other GLP-1 receptor agonist products.
May increase the risk of hypoglycemia when used with insulin or sulfonylureas in patients with type 2 diabetes.
Not recommended during pregnancy or breastfeeding.
Women of childbearing potential should use contraception during treatment.
Should be discontinued at least 2 months before a planned pregnancy.
Not recommended for patients under 18 years of age.

Active Ingredient: Semaglutide, a GLP-1 analog produced via recombinant DNA technology in yeast (Saccharomyces cerevisiae).
Available concentrations: (0.25 mg), (0.5 mg), (1 mg), (1.7 mg), (2.4 mg).
Inactive ingredients: Disodium phosphate dihydrate, sodium chloride, hydrochloric acid, sodium hydroxide, Propylene glycol, phenol, water for injection.

Store in the refrigerator at 2–8°C.
Do not freeze under any circumstances.
Single-use pens may be stored at room temperature (below 30°C) for up to 28 days.
FlexTouch pens may be used for up to 6 weeks after first use, either at room temperature or in the refrigerator.

For More Information About Semaglutide

Wegovy, 1.7 Mg, Pre-Filled Pen - 1 Pen

Overall Product Rating